<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38611">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056522</url>
  </required_header>
  <id_info>
    <org_study_id>OMS 001</org_study_id>
    <nct_id>NCT02056522</nct_id>
  </id_info>
  <brief_title>Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging</brief_title>
  <official_title>Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orlucent, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orlucent, Inc</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of MDS to access the presence of melanoma in the skin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A topical agent is applied to suspicious skin lesions and imaged. The images are analyzed to
      provide a score that correlates with the probability for the presence of melanoma in the
      lesion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To validate the performance of MDS</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To calculate and specify the PPV and NPV of the MDS for melanoma detection when used as an adjacent tool to visual skin examination.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>To further establish the safety of the MDS.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Skin Lesions</condition>
  <arm_group>
    <arm_group_label>Suspicious skin lesions.</arm_group_label>
    <description>No intervention is administered.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individual referred by a dermatologist or plastic surgeon for a skin biopsy or lesion
        excision.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with skin lesion with one or more of the ABCDE features and recommended
             for a skin biopsy.

          -  The lesion is accessible to the imaging device, with at least 1 cm of skin around the
             lesion that is accessible to the MDS.

          -  Male and female â‰¥ 21 years old.

          -  Subject is capable of giving written informed consent.

          -  Primary excision.

        Exclusion Criteria:

          -  The lesion is less than 1 cm from the eyes.

          -  The lesion is on the palms of hands or soles of the feet.

          -  Mucosal lesion.

          -  Pregnant females.

          -  Low study procedure compliance.

          -  Patients who are mentally or physically unable to comply with all aspects of the
             study.

          -  Undergoing chemotherapy.

          -  Minor or legally incompetent and not able to sign the consent form.

          -  Patient previously tested by MDS and was diagnosed with melanoma during the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehuda Ullmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yehuda Ullmann, M.D.</last_name>
    <phone>+972-50-206-1666</phone>
    <email>y_ullmann@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yehuda Ullmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>December 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Skin Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
